Futuro del CRPC. Visión 360º

3 / 28

Local
Therapy
Androgen
Deprivation
Abiraterone
Enzalutamide
Docetaxel
Cabazitaxel
Radium-223
Tumour burden
Time
NATURAL HISTORY OF PROSTATE CANCER
Hormono-sensitive Castrate-Resistant
Asymptomatic Symptomatic
Death